MCID: HYP595
MIFTS: 78

Hypertension, Essential

Categories: Genetic diseases, Cardiovascular diseases, Rare diseases, Blood diseases

Aliases & Classifications for Hypertension, Essential

MalaCards integrated aliases for Hypertension, Essential:

Name: Hypertension, Essential 53 13
Essential Hypertension 12 72 71 28 51 14 69
Hypertension 53 37 72 28 3
Eht 53 71
Hypertension, Salt-Sensitive Essential, Susceptibility to 53
Hypertension, Essential, Susceptibility to, 1 53
Hypertension, Essential, Susceptibility to, 2 53
Hypertension, Essential, Susceptibility to, 3 53
Hypertension, Essential, Susceptibility to, 4 53
Hypertension, Essential, Susceptibility to, 5 53
Hypertension, Essential, Susceptibility to, 6 53
Hypertension, Essential, Susceptibility to 53
Hypertension, Essential, Salt-Sensitive 53
Hypertension, Salt-Sensitive Essential 53
Hypertension, Susceptibility to 53
Hypertension, Essential 1 53
Hypertension, Essential 2 53
Hypertension, Essential 3 53
Hypertension, Essential 4 53
Hypertension, Essential 5 53
Hypertension, Essential 6 53
Idiopathic Hypertension 12
Primary Hypertension 12
Hypertensive Disease 69

Characteristics:

OMIM:

53
Inheritance:
multifactorial

Miscellaneous:
multiple genes influence susceptibility to hypertension. candidate genes include angiotensinogen (agt, ), angiotensin receptor-1 (agtr1, ), and beta-3 subunit of guanine nucleotide-binding protein (gnb3, ). susceptibility loci include hyt1 and hyt2 .


HPO:

31
hypertension, essential:
Inheritance multifactorial inheritance


Classifications:



External Ids:

OMIM 53 145500
Disease Ontology 12 DOID:10825
ICD9CM 34 401 401.9
NCIt 46 C3478
MedGen 39 C0085580

Summaries for Hypertension, Essential

OMIM : 53 The Pickering school held that blood pressure has a continuous distribution, that multiple genes and multiple environmental factors determine the level of one's blood pressure just as the determination of stature and intelligence is multifactorial, and that 'essential hypertension' is merely the upper end of the distribution (Pickering, 1978). In this view the person with essential hypertension is one who happens to inherit an aggregate of genes determining hypertension (and also is exposed to exogenous factors that favor hypertension). The Platt school took the view that essential hypertension is a simple mendelian dominant trait (Platt, 1963). McDonough et al. (1964) defended the monogenic idea. See McKusick (1960) and Kurtz and Spence (1993) for reviews. Swales (1985) reviewed the Platt-Pickering controversy as an 'episode in recent medical history.' The Pickering point of view appears to be more consistent with the observations. (145500)

MalaCards based summary : Hypertension, Essential, also known as essential hypertension, is related to arteries, anomalies of and pre-eclampsia, and has symptoms including elevated systolic blood pressure, elevated diastolic blood pressure and elevated mean arterial pressure. An important gene associated with Hypertension, Essential is PTGIS (Prostaglandin I2 Synthase), and among its related pathways/superpathways are Myometrial Relaxation and Contraction Pathways and Apelin signaling pathway. The drugs Adcirca and Adempas have been mentioned in the context of this disorder. Affiliated tissues include heart, kidney and testes, and related phenotypes are cardiovascular system and homeostasis/metabolism

UniProtKB/Swiss-Prot : 71 Essential hypertension: A condition in which blood pressure is consistently higher than normal with no identifiable cause.

CDC : 3 High blood pressure is a common and dangerous condition. Having high blood pressure means the pressure of the blood in your blood vessels is higher than it should be. But you can take steps to control your blood pressure and lower your risk of heart disease and stroke.About 1 of 3 U.S. adults—or about 75 million people—have high blood pressure.1Only about half (54%) of these people have their high blood pressure under control.1 This common condition increases the risk for heart disease and stroke, 2 of the leading causes of death for Americans.2Get more quick facts about high blood pressure, or learn more about high blood pressure in the United States.

Disease Ontology : 12 A hypertension with no known cause. It is the most common type of hypertension.

Wikipedia : 72 Essential hypertension (also called primary hypertension or idiopathic hypertension) is the form of... more...

Related Diseases for Hypertension, Essential

Diseases in the Familial Hypertension family:

Hypertension, Essential Hypertension, Essential 1
Hypertension, Essential 2 Hypertension, Essential 3
Hypertension, Essential 4 Hypertension, Essential 5
Hypertension, Essential 6 Hypertension, Essential 7
Hypertension, Essential 8 Malignant Essential Hypertension
Malignant Hypertension Benign Essential Hypertension
Benign Secondary Hypertension Malignant Secondary Hypertension

Diseases related to Hypertension, Essential via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 142)
# Related Disease Score Top Affiliating Genes
1 arteries, anomalies of 31.1 AGT AGTR1 NOS3 SELE
2 pre-eclampsia 31.1 AGT AGTR1 NOS2 NOS3 SELE
3 chronic kidney failure 30.9 AGT AGTR1 COL4A5 PKD1 PKD2
4 myocardial infarction 30.7 ADD1 AGT AGTR1 GNB3 NOS3 PTGIS
5 platelet membrane fluidity 30.7 NOS2 NOS3
6 kidney disease 30.7 AGTR1 COL4A5 PKD1 PKD2
7 vascular disease 30.6 NOS2 NOS3 PTGIS SELE
8 mitral valve disease 30.5 AGT AGTR1 NOS3
9 pediatric hypertension 30.5 ADD1 AGT
10 pulmonary hypertension 30.3 ECE1 NOS2 NOS3 PTGIS
11 diabetes mellitus, noninsulin-dependent 30.1 AGT AGTR1 GNB3 NOS3 SELE
12 pulmonary hypertension, primary, 1 12.5
13 malignant essential hypertension 12.3
14 benign essential hypertension 12.2
15 hypertension, essential 3 12.1
16 hypertension, essential 4 12.1
17 hypertension, essential 5 12.1
18 hypertension, essential 6 12.1
19 hypertension, essential 1 12.1
20 hypertension, essential 2 12.1
21 hypertension, essential 7 12.1
22 hypertension, essential 8 12.1
23 nephronophthisis-like nephropathy 1 10.9
24 aortic coarctation 10.8 AGT AGTR1 GNB3 NOS3
25 meningococcal infection 10.8 ADD1 AGT AGTR1
26 autosomal dominant polycystic kidney disease 10.8 ADD1 AGT NOS3 PKD1 PKD2
27 orthostatic intolerance 10.8 AGTR1 ECE1 NOS2 NOS3
28 diastolic heart failure 10.8 AGT AGTR1 NOS3
29 end stage renal failure 10.8 AGT AGTR1 COL4A5 PKD1
30 hypertension, early-onset, autosomal dominant, with severe exacerbation in pregnancy 10.8 COL4A5 F12 MEN1 PKD1 PKD2
31 ischemic optic neuropathy 10.8 AGT AGTR1 NOS3
32 autosomal genetic disease 10.7 MEN1 PKD1 PKD2
33 polycystic kidney disease 5 10.7 PKD1 PKD2
34 lymphatic malformations 10.7 PKD1 PKD2
35 atherosclerosis susceptibility 10.6 NOS3 PTGIS SELE
36 renal artery disease 10.6 AGTR1 NOS3
37 congenital hepatic fibrosis 10.5 AGTR1 PKD1
38 endotheliitis 10.5
39 cerebrovascular disease 10.3 AGTR1 F12 SELE
40 blood group, i system 10.2
41 body mass index quantitative trait locus 11 10.2
42 body mass index quantitative trait locus 9 10.2
43 body mass index quantitative trait locus 8 10.2
44 body mass index quantitative trait locus 7 10.2
45 body mass index quantitative trait locus 12 10.2
46 body mass index quantitative trait locus 14 10.2
47 body mass index quantitative trait locus 18 10.2
48 body mass index quantitative trait locus 4 10.2
49 body mass index quantitative trait locus 10 10.2
50 diabetes mellitus 10.2

Comorbidity relations with Hypertension, Essential via Phenotypic Disease Network (PDN): (show top 50) (show all 299)


Abducens Nerve Disease Acquired Polycythemia
Active Peptic Ulcer Disease Acute Closed-Angle Glaucoma
Acute Conjunctivitis Acute Cystitis
Acute Ethmoiditis Acute Kidney Failure
Acute Maxillary Sinusitis Acute Myocardial Infarction
Acute Pancreatitis Acute Stress Disorder
Acute Vascular Insufficiency of Intestine Adjustment Disorder
Adrenal Gland Disease Age-Related Hearing Loss
Alcohol Abuse Allergic Rhinitis
Allergic Urticaria Alopecia, Neurologic Defects, and Endocrinopathy Syndrome
Anxiety Aortic Aneurysm
Aortic Atherosclerosis Aortic Valve Disease 1
Asthma Atrioventricular Block
Atrophic Gastritis Atypical Depressive Disorder
Auditory System Disease Autonomic Nervous System Disease
Basilar Artery Insufficiency Bipolar Disorder
Bleeding Disorder, Platelet-Type, 11 Blepharitis
Borderline Glaucoma Borderline Personality Disorder
Brain Cancer Brain Compression
Brain Edema Brain Small Vessel Disease with or Without Ocular Anomalies
Branch Retinal Artery Occlusion Bronchitis
Buerger Disease Campylobacteriosis
Cardiac Arrest Cardiac Arrhythmia
Central Nervous System Origin Vertigo Central Retinal Artery Occlusion
Central Retinal Vein Occlusion Cerebral Arteritis

Graphical network of the top 20 diseases related to Hypertension, Essential:



Diseases related to Hypertension, Essential

Symptoms & Phenotypes for Hypertension, Essential

Symptoms via clinical synopsis from OMIM:

53
CardiovascularVascular:
elevated systolic blood pressure
elevated diastolic blood pressure
elevated mean arterial pressure


Clinical features from OMIM:

145500

Human phenotypes related to Hypertension, Essential:

31
# Description HPO Frequency HPO Source Accession
1 elevated systolic blood pressure 31 HP:0004421
2 elevated diastolic blood pressure 31 HP:0005117
3 elevated mean arterial pressure 31 HP:0004972

UMLS symptoms related to Hypertension, Essential:


equilibration disorder, tremor, edema, chest pain, angina pectoris

MGI Mouse Phenotypes related to Hypertension, Essential:

43 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.29 AGT AGTR1 ATP1B1 COL4A5 ECE1 MEN1
2 homeostasis/metabolism MP:0005376 10.28 MEN1 NOS2 NOS3 PKD1 PKD2 PTGIS
3 growth/size/body region MP:0005378 10.2 NOS2 NOS3 PKD1 PKD2 RGS5 SELE
4 hematopoietic system MP:0005397 10.13 ADD1 AGTR1 COL4A5 ECE1 NOS2 NOS3
5 immune system MP:0005387 10.11 AGT AGTR1 COL4A5 ECE1 MEN1 NOS2
6 mortality/aging MP:0010768 10.1 ADD1 AGT AGTR1 ATP1B1 COL4A5 ECE1
7 adipose tissue MP:0005375 10.04 AGT AGTR1 COL4A5 NOS2 NOS3 PKD1
8 liver/biliary system MP:0005370 9.87 AGT MEN1 NOS2 NOS3 PKD1 PKD2
9 muscle MP:0005369 9.7 AGT ATP1B1 ECE1 MEN1 NOS2 NOS3
10 normal MP:0002873 9.56 ECE1 F12 NOS3 PKD1 PKD2 RGS5
11 renal/urinary system MP:0005367 9.23 PKD2 PTGIS AGT AGTR1 COL4A5 NOS2

Drugs & Therapeutics for Hypertension, Essential

FDA approved drugs:

(show all 6)
# Drug Name Active Ingredient(s) 17 Company Approval Date
1
Adcirca 17 TADALAFIL Eli Lilly May 2009
2
Adempas 17 RIOCIGUAT Bayer Healthcare Pharmaceuticals October 2013
3
Covera-HS 17 VERAPAMIL HYDROCHLORIDE GD Searle, Alza January 1996
4
Letairis 17 AMBRISENTAN Gilead June 2007
5
Opsumit 17 MACITENTAN Actelion Pharmaceuticals October 2013
6
Remodulin 17 TREPROSTINIL United Therapeutics May 2002

Drugs for Hypertension, Essential (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 261)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ramipril Approved Phase 4,Phase 3 87333-19-5 5362129
2
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
3
Nifedipine Approved Phase 4,Phase 3,Phase 2,Phase 1 21829-25-4 4485
4
Bisoprolol Approved Phase 4 66722-44-9 2405
5
Amiloride Approved Phase 4 2609-46-3, 2016-88-8 16231
6
Amlodipine Approved Phase 4,Phase 3,Phase 2,Phase 1 88150-42-9 2162
7
Simvastatin Approved Phase 4,Phase 3 79902-63-9 54454
8
Telmisartan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 144701-48-4 65999
9
Felodipine Approved, Investigational Phase 4,Phase 3 72509-76-3 3333
10
Irbesartan Approved, Investigational Phase 4,Phase 3,Phase 2 138402-11-6 3749
11
Metoprolol Approved, Investigational Phase 4,Phase 3,Phase 2 51384-51-1, 37350-58-6 4171
12
Enalapril Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 75847-73-3 40466924 5362032
13
Enalaprilat Approved Phase 4,Phase 3,Phase 2,Phase 1 76420-72-9 6917719
14
Hydrochlorothiazide Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 58-93-5 3639
15
Losartan Approved Phase 4,Phase 3,Phase 2,Phase 1 114798-26-4 3961
16
Valsartan Approved, Investigational Phase 4,Phase 3,Phase 2 137862-53-4 60846
17
Lisinopril Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 83915-83-7, 76547-98-3 5362119
18
Metformin Approved Phase 4 657-24-9 4091 14219
19
Olmesartan Approved, Investigational Phase 4,Phase 3,Phase 2 144689-24-7, 144689-63-4 158781 130881
20
Carvedilol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 72956-09-3 2585
21
Spironolactone Approved Phase 4,Phase 3,Phase 2 1952-01-7, 52-01-7 5833
22
Benzocaine Approved, Investigational Phase 4,Phase 3 1994-09-7, 94-09-7 2337
23
Nitric Oxide Approved Phase 4,Phase 2,Phase 1 10102-43-9 145068
24
Eprosartan Approved Phase 4,Phase 3 133040-01-4 5281037
25
Lercanidipine Approved, Investigational Phase 4,Phase 3,Phase 2 100427-26-7 65866
26
Atenolol Approved Phase 4,Phase 3 29122-68-7 2249
27 Lacidipine Approved, Investigational Phase 4,Phase 3 103890-78-4
28
Doxazosin Approved Phase 4,Phase 2,Phase 3 74191-85-8 3157
29
Nebivolol Approved, Investigational Phase 4,Phase 3,Phase 2 152520-56-4, 118457-14-0, 99200-09-6 71301
30
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
31
Iloprost Approved, Investigational Phase 4 78919-13-8 6443959
32
Allopurinol Approved Phase 4,Phase 2 315-30-0 2094
33
Eplerenone Approved Phase 4,Phase 3,Phase 2 107724-20-9 443872 150310
34
Hydralazine Approved Phase 4 86-54-4 3637
35 Benidipine Approved, Investigational Phase 4 105979-17-7
36
Indapamide Approved Phase 4,Phase 3 26807-65-8 3702
37
Quinapril Approved, Investigational Phase 4 85441-61-8 54892
38
Spirapril Approved Phase 4 83647-97-6 5311447
39
Chlorthalidone Approved Phase 4,Phase 3 77-36-1 2732
40 Manidipine Approved, Investigational Phase 4 89226-50-6
41
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 59-30-3 6037
42
leucovorin Approved, Nutraceutical Phase 4,Phase 2,Phase 3 58-05-9 143 6006
43 tannic acid Approved, Nutraceutical Phase 4,Phase 3
44
Niacin Approved, Investigational, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 59-67-6 938
45
Nicotinamide Approved, Investigational, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 98-92-0 936
46 Tomato Approved, Nutraceutical Phase 4
47
Candesartan Experimental Phase 4,Phase 3,Phase 2,Phase 1 139481-59-7 2541
48
Maleic acid Experimental Phase 4 110-16-7 444266
49
Uric Acid Experimental, Investigational Phase 4,Phase 2,Phase 3 69-93-2 1175
50
Canrenone Investigational Phase 4 976-71-6 13789

Interventional clinical trials:

(show top 50) (show all 544)

# Name Status NCT ID Phase Drugs
1 Safety and Efficacy of Ramipril in the Treatment of Essential Hypertension Unknown status NCT00366119 Phase 4 Ramipril
2 GRK4 Polymorphisms Blood Pressure Response to Candesartan Unknown status NCT01629225 Phase 4 Candesartan
3 A Study of Nifecardia SRFC and Adalat OROS in the Treatment of Patients With Essential Hypertension Unknown status NCT00173667 Phase 4 Nifedipine 30 mg GITS
4 BRAVE Study With Uncontrolled Essential Hypertension (BRAVE Study) Unknown status NCT02398929 Phase 4 Bisoprolol 2.5 mg;Placebo
5 Effect of Nifedipine GITS in Patients With Mild-to-moderate Primary Hypertension Unknown status NCT02641821 Phase 4 Nifedipine GITS
6 Effects of Angiotensin II Receptor Blocker Compared With Diuretics in High-risk Hypertensive Patients Unknown status NCT01011660 Phase 4 Amlodipine, Telmisartan, Amiloride Compound , Simvastatin
7 Combined Antihypertensive Therapy and Sexual Dysfunction Unknown status NCT01238705 Phase 4 Felodipine add Irbesartan;Felodipine add Metoprolol
8 Efficacy Study of Nifedipine Controlled-Release Tablets (Xin Ran) to Treat Early Morning Blood Pressure and Central Arterial Pressure Unknown status NCT02357615 Phase 4 nifedipine CR tablets (Xin Ran);Adalat
9 Treatment of HYpertension: Morning Versus Evening Unknown status NCT02214498 Phase 4 Enalapril/hydrochlorothiazide;Placebo
10 Home Blood Pressure in Hypertension Management Unknown status NCT00841308 Phase 4
11 Valsartan and Amlodipine Compared to Losartan and Amlodipine in Hypertensive Patients Unknown status NCT00716950 Phase 4 valsartan/amlodpine;losartan/amlodpine
12 Dose Titration of Lisinopril in Children Aged 1 to 18 Years With Primary or Secondary Hypertension Unknown status NCT02184858 Phase 4 lisinopril, ACE-inhibitor
13 Danshen Dropping Pill for Coronary Heart Disease Heart and Artery Structure and Function Unknown status NCT01825759 Phase 4 danshen dripping pill
14 Monotherapy Versus Dual Therapy for Initial Treatment for Hypertension Unknown status NCT00994617 Phase 4 Losartan and hydrochlorothiazide;Hydrochlorothiazide switched over with Losartan at 8 weeks
15 Losartan and Simvastatin in Hypertensive Obeses With Liver Steatosis Unknown status NCT00669435 Phase 4 Losartan + Simvastatin;Amlodipine + Simvastatin
16 Effects of Valsartan and Aliskiren on Hemostatic Indices in Hypertensive Diabetics Unknown status NCT01095822 Phase 4 Aliskiren + Valsartan
17 Efficacy and Safety of Levamlodipine Besylate Compared to Amlodipine Maleate in Patients With Essential Hypertension Completed NCT01131546 Phase 4 Levamlodipine besylate;Amlodipine maleate
18 Canrenone as Add-on in Patients With Essential Hypertension Completed NCT02687178 Phase 4 Canrenone 50 vs canrenone 100 mg
19 Efficacy Study of Nifedipine Controlled-Release Tablets (Xin Ran) to Treat Mild to Moderate Essential Hypertension Completed NCT02031861 Phase 4 nifedipine CR tablets (Xin Ran);nifedipine CR tablets (Adalat)
20 The Effect of Eprosartan on Hormones and Kidney Function in Patients With Essential Hypertension Completed NCT00438945 Phase 4 Eprosartan
21 A Study to Explore the Effects of Azilsartan Compared to Telmisartan on Insulin Resistance of Patients With Essential Hypertension on Type 2 Diabetes Mellitus by HOMA-R Completed NCT02079805 Phase 4 Azilsartan;Telmisartan
22 Azilsartan Medoxomil in the Treatment of Essential Hypertension and Type 2 Diabetes in Asia Completed NCT02517866 Phase 4 Azilsartan Medoxomil
23 Intensive Vasodilator Therapy in Patients With Essential Hypertension Completed NCT01180413 Phase 4 Amlodipine;Ramipril;Lercanidipine;Losartan
24 Effects of Bisoprolol and Atenolol on Sympathetic Nervous Activity and Central Aortic Pressure in Patients With Essential Hypertension Completed NCT01762436 Phase 4 bisoprolol;atenolol
25 Efficacy and Safety of Olmesartan Medoxomil in Stage 1 and 2 Essential Hypertension Completed NCT00890591 Phase 4 olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessary
26 Lacidipine In Mild To Moderate Essential Hypertension Patients With Type 2 Diabetes In Korea Completed NCT00328965 Phase 4 Lacidipine
27 Efficacy and Safety of Once Daily Dosing of Aliskiren (300 mg (qd) Once a Day) to Twice Daily Dosing of Aliskiren (150 mg (Bid) Twice a Day) in Treating Moderate Hypertension. Completed NCT00654875 Phase 4 Aliskiren;Placebo to Aliskiren
28 A Study on Molecular Genetics of Drug Responsiveness in Essential Hypertension Completed NCT03276598 Phase 4 Amlodipine;Bisoprolol;Hydrochlorothiazide;Losartan;Placebo
29 The Efficacy and Safety of OROSARTAN® Versus CODIOVAN® in Patients With Essential Hypertension Uncontrolled With Monotherapy Completed NCT02433119 Phase 4 OROSARTAN® 5/160mg;CODIOVAN® 160/12.5mg
30 A Randomized Controlled Study to Assess the Effects of Bisoprolol and Atenolol on Resting Heart Rate and Sympathetic Nervous System's Activity in Subjects With Essential Hypertension Completed NCT01251146 Phase 4 Bisoprolol;Atenolol
31 A Study Evaluating the Gastrointestinal (GI) Safety and Tolerability of Aliskiren Compared to Ramipril in Essential Hypertension Completed NCT00631917 Phase 4 Aliskiren;Ramipril
32 Effects of Combination Therapy With Alpha-1 Blocker (Bunazosin or Doxazosin) in the Treatment of Patients With Mild to Moderate Essential Hypertension Completed NCT00130156 Phase 4 Bunazosin;Doxazosin;Valsartin
33 Micardis® in Patients With Essential Hypertension Completed NCT02187705 Phase 4 Telmisartan tablets
34 Comparison of Awakening Versus Bedtime Dosing of Ramipril in Subjects With Essential Hypertension Completed NCT00473174 Phase 4 Ramipril
35 Diuretics In the Management of Essential Hypertension (DIME) Study Completed NCT00131846 Phase 4 Thiazide diuretics;No diuretics
36 A Study to Compare the Efficacy, Safety and Tolerability of Selomax With Its Individual Components Completed NCT00819104 Phase 4 Metoprolol XL 50mg + Amlodipine 5mg;Metoprolol XL 25 mg + Amlodipine 2.5mg;Metoprolol XL 50mg;Metoprolol XL 25 mg;Amlodipine 5mg
37 A Study of Safety and Efficacy in MK-0954A Combination in Participants With Hypertension (MK-0954A-373 AM3) Completed NCT01431508 Phase 4 Losartan 50 mg / HCTZ 12.5 mg
38 Study of Efficacy and Safety of CVAA489 in Hypertensive Patients Completed NCT02062645 Phase 4 amlodipine/valsartan
39 Efficacy and Safety of Metoprolol Succinate Prolonged-Release Tablet in Patients With Mild to Moderate Hypertension Completed NCT00861016 Phase 4 metoprolol succinate prolonged-release tablet and felodipine
40 Controlled Release Nifedipine and Valsartan Combination Therapy in Patients With Essential Hypertension Completed NCT01518855 Phase 4 Nifedipine (Adalat, BAYA1040);Amlodipine (Norvasc);Diovan
41 Effectiveness of MICARDIS® (Telmisartan) on Blood Pressure Control and Quality of Live in Patients With Essential Hypertension Completed NCT02242370 Phase 4 Low dose of telmisartan;High dose of telmisartan
42 Effect of the Fixed Dose Combination Amlodipine/Valsartan on Central Aortic Blood Pressure in Uncontrolled Essential Hypertension With Amlodipine 5 mg Completed NCT00687973 Phase 4 Valsartan/amlodipine 80/5 mg tablets;Amlodipine 5 mg capsules;Amlodipine 10 mg capsules;Atenolol 50 mg tablets;Atenolol 100 mg tablets
43 Efficacy of Aliskiren Compared to Ramipril in the Treatment of Moderate Systolic Hypertensive Patients Completed NCT01042392 Phase 4 Aliskiren;Ramipril;Matching placebo to Aliskiren;Matching placebo to Ramipril
44 China Stroke Primary Prevention Trial Completed NCT00794885 Phase 4 Enalapril/folic acid;Enalapril maleate
45 Efficacy and Tolerability of an Aliskiren-based Treatment Algorithm in Patients With Mild to Moderate Hypertension Completed NCT00765947 Phase 4 Aliskiren;Hydrochlorothiazide;Amlodipine
46 Hydrochlorothiazide (+) Losartan Potassium vs. Amlodipine Comparative Study (0954A-314) Completed NCT00157963 Phase 4 MK0954A; hydrochlorothiazide (+) losartan potassium / Duration of Treatment: 12 weeks
47 PMS Study of Amlodipine/Valsartan for the Treatment of Hypertension Completed NCT02058446 Phase 4 Amlodipine/Valsartan
48 Hybrid Blood Pressure Monitor Validation Completed NCT01120990 Phase 4
49 Calcium Channel Blockers (CCBs) or Diuretics as an Add-on to Olmesartan Medoxomil in Hypertension Completed NCT00858702 Phase 4 olmesartan medoxomil and a CCB;olmesartan medoxomil and a diuretic
50 Low-dose Nifedipine-Valsartan Combination Compared to Up-titrated Valsartan Monotherapy in Essential Hypertension Completed NCT00993109 Phase 4 Adalat (Nifedipine, BAYA1040);Diovan (Valsartan)

Search NIH Clinical Center for Hypertension, Essential

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Genetic Tests for Hypertension, Essential

Genetic tests related to Hypertension, Essential:

# Genetic test Affiliating Genes
1 Essential Hypertension 28 ADD1 AGT AGTR1 ATP1B1 CYP3A5 ECE1 GNB3 NOS2 NOS3 PTGIS RGS5 SELE
2 Hypertension 28

Anatomical Context for Hypertension, Essential

MalaCards organs/tissues related to Hypertension, Essential:

38
Heart, Kidney, Testes, Smooth Muscle, Liver, Endothelial, Lung

Publications for Hypertension, Essential

Articles related to Hypertension, Essential:

(show top 50) (show all 2076)
# Title Authors Year
1
Association of endothelin-1 gene polymorphisms with essential hypertension in a Chinese population. ( 28692114 )
2017
2
Up-regulation of gap junction in peripheral blood T lymphocytes contributes to the inflammatory response in essential hypertension. ( 28910394 )
2017
3
Expression and methylation of circulating microRNA-510 in essential hypertension. ( 27881848 )
2017
4
Hydrochlorothiazide treatment increases the abundance of the NaCl cotransporter in urinary extracellular vesicles of essential hypertensive patients. ( 28274929 )
2017
5
Association of NOS3 gene polymorphisms with essential hypertension in Sudanese patients: a case control study. ( 29132319 )
2017
6
Association of connexin gene polymorphism with essential hypertension in Kazak and Han Chinese in Xinjiang, China. ( 28397038 )
2017
7
A novel haplotype of low-frequency variants in the aldosterone synthase gene among northern Han Chinese with essential hypertension. ( 28953657 )
2017
8
Circulating miRNA29 family expression levels in patients with essential hypertension as potential markers for left ventricular hypertrophy. ( 28287884 )
2017
9
Assessment of subclinical left ventricular changes in essential hypertensive patients with hyperuricemia: A three-dimensional speckle-tracking echocardiography study. ( 28072551 )
2017
10
Relationship between ADD1 Gly460Trp gene polymorphism and essential hypertension in Madeira Island. ( 29049185 )
2017
11
The Mitochondrial tRNA(Ala) T5655C Mutation May Modulate the Phenotypic Expression of tRNA(Met) and tRNA(Gln) A4401G Mutation in a Han Chinese Family With Essential Hypertension. ( 28111408 )
2017
12
Genetic determinants of essential hypertension in the population of Tatars from Russia. ( 28350619 )
2017
13
Susceptiveness of Vitamin K epOxide Reductase Complex Subunit 1 Gene Polymorphism in Essential Hypertension. ( 28281786 )
2017
14
Positive association between ALDH2 rs671 polymorphism and essential hypertension: A case-control study and meta-analysis. ( 28472173 )
2017
15
Serum soluble RAGE level inversely correlates with left ventricular hypertrophy in essential hypertension patients. ( 27421025 )
2016
16
Serum uric acid is associated with non-dipping circadian pattern in young patients (30-40 years old) with newly diagnosed essential hypertension. ( 26817828 )
2016
17
Interactions between CYP11B2 Promoter Methylation and Smoking Increase Risk of Essential Hypertension. ( 28078278 )
2016
18
Reduced Expression of the Extracellular Calcium-Sensing Receptor (CaSR) Is Associated with Activation of the Renin-Angiotensin System (RAS) to Promote Vascular Remodeling in the Pathogenesis of Essential Hypertension. ( 27391973 )
2016
19
Genetic Analysis of the Atrial Natriuretic Peptide Gene Polymorphisms among Essential Hypertensive Patients in Malaysia. ( 27413750 )
2016
20
[Association of the -844G>A polymorphism in the catalase gene with the increased risk of essential hypertension in smokers]. ( 27735913 )
2016
21
Novel Association of WNK4 Gene, Ala589Ser Polymorphism in Essential Hypertension, and Type 2 Diabetes Mellitus in Malaysia. ( 27314050 )
2016
22
Role of tagged SNPs of the AGT gene in causing susceptibility to essential hypertension. ( 27398822 )
2016
23
Gender-Specific Association of ATP2B1 Variants with Susceptibility to Essential Hypertension in the Han Chinese Population. ( 26933664 )
2016
24
Polymorphisms of APLN-APLNR system are associated with essential hypertension in Mexican-Mestizo individuals. ( 27450650 )
2016
25
Polymorphisms and haplotype of ROCK2 associate with high altitude essential hypertension in native high altitude Ladakhi Indian population: a preliminary study. ( 26818475 )
2016
26
Haplotype association and synergistic effect of human aldosterone synthase (CYP11B2) gene polymorphisms causing susceptibility to essential hypertension in Indian patients. ( 27935319 )
2016
27
Association of paraoxonase 1 (PON1) gene polymorphisms and concentration with essential hypertension. ( 27668323 )
2016
28
The relationship between MTHFR C677T gene polymorphism and essential hypertension in a sample of an Algerian population of Oran city. ( 27780089 )
2016
29
CYP11B2 gene polymorphism and essential hypertension among Tibetan, Dongxiang and Han populations from northwest of China. ( 27149293 )
2016
30
Association of the Glu504Lys polymorphism in the aldehyde dehydrogenase 2 gene with endothelium-dependent dilation disorder in Chinese Han patients with essential hypertension. ( 26691593 )
2016
31
Aldose reductase C-106T polymorphism is associated with the risk of essential hypertension. ( 27343777 )
2016
32
Serum neuron specific enolase could predict subclinical brain damage and the subsequent occurrence of brain related vascular events during follow up in essential hypertension. ( 27000243 )
2016
33
Mitochondrial DNA mutation m.5512A > G in the acceptor-stem of mitochondrial tRNA(Trp) causing maternally inherited essential hypertension. ( 27687549 )
2016
34
Association between the C34T polymorphism of the AMPD1 gene and essential hypertension in Malaysian patients. ( 27323204 )
2016
35
Association of Polymorphisms in the Atrial Natriuretic Factor Gene with the Risk of Essential Hypertension: A Systematic Review and Meta-Analysis. ( 27136577 )
2016
36
The Association of Mitofusion-2 Gene Polymorphisms with Susceptibility of Essential Hypertension in Northern Han Chinese Population. ( 26816493 )
2016
37
Association between Carotid Intima-media Thickness and Aldehyde Dehydrogenase 2 Glu504Lys Polymorphism in Chinese Han with Essential Hypertension. ( 27270535 )
2016
38
Association of SCNN1B promoter methylation with essential hypertension. ( 27840946 )
2016
39
AGTR1 has undergone natural selection in Euro-Asian populations in relation to ambient temperature that predisposes Chinese populations to essential hypertension. ( 26901789 )
2016
40
Synergistic effects of gene polymorphisms of the renin-angiotensin-aldosterone system on essential hypertension in Kazakhs in Xinjiang. ( 26305278 )
2016
41
Case-control study on association of peroxisome proliferator-activated receptor-I' and SNP-SNP interactions with essential hypertension in Chinese Han population. ( 26613934 )
2016
42
Association between the MTHFR C677T gene polymorphism and essential hypertension in South West Cameroon. ( 27051013 )
2016
43
The rs3754777 polymorphism of the STK39 gene is associated with essential hypertension in central south Chinese Han males. ( 26911228 )
2016
44
Single nucleotide polymorphism of adiponectin +276 G/T is associated with the susceptibility to essential hypertension in a Turkish population. ( 27936341 )
2016
45
A Novel Polymorphism of the CYP19 Gene is Associated with Essential Hypertension in China. ( 27012050 )
2016
46
Biochemical and genetic role of apelin in essential hypertension and acute coronary syndrome. ( 27543713 )
2016
47
1H nuclear magnetic resonance-based metabolomic study on efficacy of Qingrehuatan decoction against abundant phlegm-heat syndrome in young adults with essential hypertension. ( 25842725 )
2015
48
Impaired neuronal nitric oxide synthase-mediated vasodilator responses to mental stress in essential hypertension. ( 25733243 )
2015
49
Association of regulator of G protein signaling (RGS5) gene variants and essential hypertension in Mongolian and Han populations. ( 26782409 )
2015
50
Gender-Specific Effect of CYP2C8*3 on the Risk of Essential Hypertension in Bulgarian Patients. ( 26404779 )
2015